Emergent BioSolutions (EBS) Tops Q1 EPS by 142c, provides guidanvce
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.80 -3.13%
EPS Growth %: -138.7%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -138.7%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.59, $1.42 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $300.4 million versus the consensus estimate of $185.4 million.
GUIDANCE:
Emergent BioSolutions sees FY2024 revenue of $1-1.1 billion, versus the consensus of $1.015 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Anthropic delays planned IPO from October to November - WSJ
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
